Combination Products Part 4 Compliance and Implementation at multi-site Network
|
|
- Cora Flynn
- 6 years ago
- Views:
Transcription
1 Combination Products Part 4 Compliance and Implementation at multi-site Network Vijay Damodaran Eli Lilly & Company September 27, 2017
2 Contents Key cgmp requirements for combination products How to perform effective compliance oversight when multiple sites are involved in design, development and manufacturing of combination products? Compliance to EU requirements for drug/device medicinal products Inspection readiness for combination products 2017 Eli Lilly and Company 2
3 Combination Product Definitions Combination Product: Per 21 CFR Part 3, a combination product is a product composed of any combination of drug, device or biological product i.e. /Drug, /Biologic, Drug/Biologic or /Drug/Biologic Types: Combination Product Types per 21 CFR 3.2 (e) Single entity Co-packaged Cross-labeled Constituent Parts: Drug, device and biologic products in the combination products are referred as constituent parts 2017 Eli Lilly and Company 3
4 Combination Product Definitions Component: Under and 210.3, refers to ingredients, any raw material, plastic components, sub-assemblies. CMOs that manufacture molded plastic parts, subassemblies are not subject to QS regulation Drug Containers versus delivery devices: If the article merely holds the drug - only subject to drug cgmps e.g. cartridge, vials, ampules etc. However, if the article holds the drug and also delivers the drug it is a combination product e.g. PFS Manufacture: per 21 CFR part 4.2 includes, but is not limited to, designing, fabricating, assembling, filling, processing, testing, labeling, packaging, repackaging, holding and storage 2017 Eli Lilly and Company 4
5 21 CFR Part 4 On July 22, 2013 FDA final rule 21 CFR Part 4 cgmp Requirements for Combination Products became effective FDA released a draft guidance in Jan 2015 and final guidance in Jan 2017 cgmp Requirements for Combination Products to explain the final rule Note: Part 4 does not include any new requirements - it merely clarifies how to implement existing regulations for combination products 210/211, Eli Lilly and Company 5
6 21 CFR Part 4 No grand-fathering No transition time, effective as of July 22, 2013 FDA is sending teams of both pharmaceutical and medical device inspectors to review and inspect against 21 CFR Part 4 FDA has started enforcement actions e.g. warning letters 2017 Eli Lilly and Company 6
7 21 CFR Part 4 - Implementation For cross-labeled combination product: 21 CFR parts 210/211 will apply to the drug constituent part and 21 CFR part 820 will apply to the device constituent part For Single-entity and Co-packaged combination products, part 4 offers options 2017 Eli Lilly and Company 7
8 21 CFR Part 4: Single-entity & Copackaged Combination Products Part 4 offers following options: Option 1 Drug cgmps (210/211, ) + QSR (820) Note: With the streamlined approach, manufacturer can choose option 2 or 3 irrespective of PMOA Option 2 Drug cgmps (210/211, ) + QSR Specific Provisions Option 3 Drug cgmps Specific Provisions + QSR (820) Streamlined approach 2017 Eli Lilly and Company 8
9 Option 2 Streamlined approach Implement Drug cgmps and the following provisions from the QS regulation Drug cgmps (210/211, ) + QSR Specific Provisions 21 CFR 820 Quality Element 21 CFR Management Responsibility 21 CFR Design Controls 21 CFR Purchasing Controls 21 CFR CAPA 21 CFR Installation (N/A for PFS/Auto-Injectors/Pen Injectors) X 21 CFR Servicing (N/A for PFS/Auto-Injectors/Pen Injectors) X 2017 Eli Lilly and Company 9
10 Option 3 Streamlined approach Implement QS regulation and the following provisions from the Drug cgmp Drug cgmps Specific Provisions + QSR (820) 21 CFR 211 Quality Element 21 CFR Testing of components, drug product containers and closures 21 CFR Calculation of yield 21 CFR Tamper evident packaging requirements for OTC products 21 CFR Expiration dating 21 CFR Testing and release for distribution 21 CFR Stability testing 21 CFR Special testing requirements 21 CFR Reserve samples 2017 Eli Lilly and Company 10
11 Streamlined Approach FDA expects manufacturers who follow stream lined approach clearly identify and document what base GMP operating system is used and which special provisions are applicable for each facility In addition, FDA expects manufacturers to clearly show how they meet applicable cgmp and QSR requirements under the stream lined approach 2017 Eli Lilly and Company 11
12 Example Supply Chain Single Entity Combination Product Marketed in US CMO 1 components/subassembly CMO 2 components/subassembly Site 2 DP Mfg/Filling Site 3 CP Final Sites 3, 4 CP Final Site 5 CP Labeling/ Packaging Site 6 CP Holding & Storage/ Distribution Site 1 CP Design Controls MD Mfg. CMO 3 CP Final CMO 4 CP Testing company facilities Medical Manufacturing 2017 Eli Lilly and Company 12
13 Key Compliance Questions Which sites are subject to Part 4? What base cgmp operating system may be used at various sites? Where could Part 4 compliance and streamlined approach be documented? Overall, who is responsible for coordinating and ensuring compliance with Part 4? 2017 Eli Lilly and Company 13
14 Which Sites are subject to Part 4? CMO 1 components/subassembly CMO 2 components/subassembly Site 2 DP Mfg/Filling Site 3 CP Final Sites 3, 4 CP Final Site 5 CP Labeling/ Packaging Site 6 CP Holding & Storage/ Distribution Site 1 CP Design Controls MD Mfg. CMO 3 CP Final CMO 4 CP Testing Sites subject to Part 4 Note: Not all GMP requirements may apply at a facility. Each of these facilities must be in compliance with the requirements applicable to the manufacturing process that occurs at that facility 2017 Eli Lilly and Company 14
15 What Base cgmp Operating System may be used at various sites? Base 820 QS Regulation Operating System: Site 1 (for CP Mfg.) 21 CFR 211 Quality Element Applicability 21 CFR Testing and approval or rejection of components, drug product N/A containers and closures 21 CFR Calculation of yield N/A 21 CFR Tamper evident packaging requirements for OTC human drug N/A products 21 CFR Expiration dating Yes 21 CFR Testing and release for distribution N/A 21 CFR Stability testing Yes 21 CFR Special testing requirements N/A 21 CFR Reserve samples N/A Site 1 CP Design Controls CMO 1 components/ sub-assembly CMO 2 components/ sub-assembly MD Mfg. Site 2 DP Mfg/Filling Sites 3, 4 CP Final CMO 3 CP Final Site 5 CP Labeling/ Packaging CMO 4 CP Testing Site 6 CP Holding & Storage/ Distribution Sites subject to Part Eli Lilly and Company 15
16 What Base cgmp Operating System may be used at various sites? Base Drug cgmp Operating System: Sites: 3, 4, 5, 6 and CMO Sites: 3,4 21 CFR 820 Quality Element Applicability 21 CFR Management Responsibility Yes 21 CFR Design Controls N/A* (design transfer may apply) 21 CFR Purchasing Controls Yes 21 CFR CAPA Yes 21 CFR Installation N/A 21 CFR Servicing N/A Site 1 CP Design Controls CMO 1 components/ sub-assembly CMO 2 components/ sub-assembly MD Mfg. Site 2 DP Mfg/Filling Sites 3, 4 CP Final CMO 3 CP Final Site 5 CP Labeling/ Packaging CMO 4 CP Testing Site 6 CP Holding & Storage/ Distribution Sites subject to Part Eli Lilly and Company 16
17 Where could the streamlined approach be documented? Premarket submissions Quality Manual Quality Agreements FDA expects companies to document and demonstrate compliance to Part 4. Need to clearly identify if streamlined approach is used and what base cgmp operating system is utilized at each facility 2017 Eli Lilly and Company 17
18 Governance in a multi-site MD/CP network Site 1 CP Design Controls Sites subject to Part 4 CMO 1 components/subassembly CMO 2 components/subassembly MD Mfg. Site 2 DP Mfg/Filling Site 3 CP Final Sites 3, 4 CP Final CMO 3 CP Final Site 5 CP Labeling/ Packaging CMO 4 CP Testing Site 6 CP Holding & Storage/ Distribution How to coordinate and ensure compliance in a multi-site network? 2017 Eli Lilly and Company 18
19 Medical Network Combination Products Network Governance in a multi-site MD/CP network one approach Central Office IAF MD1 Model Audits Mgmt. Reviews Central Site CAPA QS Gap Analysis CP Owner Part 4 model 2017 Eli Lilly and Company 19
20 Single Quality Manual for Sites Governance in a multi-site MD/CP network one approach Site 5 CP labeling/ Packaging Site 4 CP Final Site 6 CP Holding/ Distribution Site 3 CP Final Site 1 CP Owner CMO 1 Subassembly CMO 4 CP Testing CMO 2 Subassembly CMO 3 CP Final Site 1 CP Owner Coordination and oversight of multi-site CP network Audits Mgmt. Reviews QS Compliance CP Design Controls Complaints Handling Specs CP Risk Management CMO Supplier Quality Note: Site 2 is a DP filling site and is excluded from this central oversight 2017 Eli Lilly and Company 20
21 Combination Products in EU Currently no legal definition for Combination Products in EU IN EU, combination products (PMOA: Drug) that are integrated together, that are not reusable and are intended for use only in that combination are considered Medicinal Products and follow MPD (2001/83/EC) However, relevant safety and performance requirements from Annex I of MDD 93/42/EEC is applicable Multiple ISO standards (e.g , 14971, 10993, 60601) are used to show presumption of conformity with Essential Requirements in Annex I 2017 Eli Lilly and Company 21
22 Combination Products in EU Currently minimal requirements in MPD (2001/83/EC, amended by 2012/26/EU) on device components of Medicinal Products Article 117 of new MDR (2017/745) amends MPD 2001/83/EC. The dossier for marketing authorization shall include results of assessment and evidence of conformity with safety and performance requirements in Annex 1 of MDR some options: EU Declaration of Conformity CE Marking Opinion from NB on the conformity of device with safety and performance requirements in Annex I of MDR 2017 Eli Lilly and Company 22
23 Combination Products in EU EMA/QWP/BWP/CHMP issued a concept paper on developing guideline for quality requirements of medicinal products containing device components -start of public consultation: 16 Feb end of public consultation: 16 May 2017 Following receipt and review of concept paper comments, a draft guidance will be released for a 6 month external consultation 2017 Eli Lilly and Company 23
24 Single Quality Manual for Sites Governance in a multi-site MD/CP network one approach Site 5 CP labeling/ Packaging Site 4 CP Final Site 6 CP Holding/ Distribution Site 3 CP Final Site 1 CP Owner CMO 1 Subassembly CMO 4 CP Testing CMO 2 Subassembly CMO 3 CP Final Site 1 CP Owner Coordination and oversight of multi-site CP network Audits Mgmt. Reviews QS Compliance CP Design Controls Complaints Handling Specs CP Risk Management CMO Supplier Quality Note: Site 2 is a DP filling site and is excluded from this central oversight 2017 Eli Lilly and Company 24
25 Single Quality Manual for MD/CP Sites Single ISO certification for MD/CP multi-site network central office model With the harmonization of ISO with global requirements especially 820 QSR, one approach is to obtain ISO single certification for all MD/CP sites under central site - Site 1 Site 3 CMO 4 Site 4 Site 1 Single ISO certification Site 6 CMO 1 Site 1 Purchasing Controls CMO 3 Site 5 CMO Eli Lilly and Company 25
26 Key Takeaways FDA expects manufacturers who follow stream lined approach clearly identify and document what base GMP operating system is used and, in addition, demonstrate compliance to appropriate requirements New EU MDR has amended MPD and has clarified requirements for device conformity to be included in marketing authorization dossier of medicinal product With a multi-site network associated with combination product manufacturing, it is recommended that central oversight be provided across multiple facilities 2017 Eli Lilly and Company 26
27 Questions 2017 Eli Lilly and Company 27
PDA & West Present: Combination Products Combination Product Hot Topics: Post Approval Device Changes and the New EU MDR Article 117 Requirements
PDA & West Present: Combination Products Combination Product Hot Topics: Post Approval Device Changes and the New EU MDR Article 117 Requirements Doug Mead, Sr. Director, CMC RA, Devices and Combination
More informationGuidance for Industry and FDA:
1227 25th St., NW Washington, DC 20037-1156 Guidance for Industry and FDA: Application of cgmp Regulations to Combination Products: Frequently Asked Questions PROPOSED GUIDANCE January 15, 2007 This guidance
More informationISPE Annual Meeting 29 October 1 November 2017 San Diego, CA. Combination Product Updates, Initiatives, and Case Studies. Steven B. Hertz, P.E.
Combination Product Updates, Initiatives, and Case Studies Steven B. Hertz, P.E. Consumer Safety Officer, FDA/CDER/OPQ Agenda 1: CP Overview 2: CDER Updates : CP Application Info : Case Studies 5: Summary
More informationCombination Products Workshop: CGMP and PMSR Requirements. GMP by the Sea August 28, Mark D. Kramer Regulatory Strategies, Inc.
Combination Products Workshop: CGMP and PMSR Requirements GMP by the Sea August 28, 2017 Mark D. Kramer Regulatory Strategies, Inc. 1 Definition of a Combination Product A combination of a drug, device
More informationGlobal Regulatory Affairs
Navigating the Regulatory Landscape for Combination Products Presented by: Becky Leibowitz, Ph.D. Associate Director, RA-CMC, Medical Devices & Combination Products Janssen Research & Development, LLC
More informationRegulatory perspectives on CQAs, CPPs, and Risk Analyses for Combination Products.
Regulatory perspectives on CQAs, CPPs, and Risk Analyses for Combination Products. 3rd FDA/PQRI Conference on Advancing Product Quality March 22-24, 2017 TRACK #2 Achieving Drug Product Quality: Novel
More informationCOMBINATION PRODUCTS. Karyn M. Campbell, Director Investigations Branch Philadelphia District Office Food and Drug Administration
COMBINATION PRODUCTS Karyn M. Campbell, Director Investigations Branch Philadelphia District Office Food and Drug Administration Regulations 78 Federal Register (78 FR) 4307, published 1/22/13, effective
More informationCombination products Updates Final FDA Guidance
Compliance Seminars Combination products Updates Final FDA Guidance Presented by Anna Lundén Webinar, March 8, 2017 Intentionally blank Compliance Seminars Our international course program for GMP professionals
More informationQuality System Regulation (QSR) Training
Quality System Regulation (QSR) Training Or How to Ensure Development, Production and Sale of Safe, Effective, Consistent Product FDLI February 2003 Overview QSR History, Purpose and Scope Changes from
More informationGMP GUIDELINES. GMP Guides from Industry Organisations. FDA cgmp WHO GMP. cgmp Guide Drugs 21 CFR 210 GAMP. ISPE Technical Guides
FDA cgmp cgmp Guide Drugs 21 CFR 210 cgmp Guide Drugs 21 CFR 211 cgmp Guide Medical Device 21 CFR 808, 812, 820 cgmp Guide Biologics 21 CFR 600, 606, 610 Guideline List Human Drugs Guideline List Biologics
More informationRegulatory Challenges of Combination Products in EU and US. Afternoon seminar, 24 January 2018 by COBIS and IWA Consulting
Regulatory Challenges of Combination Products in EU and US Afternoon seminar, 24 January 2018 by COBIS and IWA Consulting 1 1 Content Introductions by COBIS and IWA Consulting Definition of combination
More informationFOREIGN DRUG INSPECTION/AUDITS FROM THE FDA PERSPECTIVE
FOREIGN DRUG INSPECTION/AUDITS FROM THE FDA PERSPECTIVE Robert C. Fish EAS Consulting Group, LLC. Statistics About 80% of world supply of APIs from India and China Some API produced in Korea, but little
More informationSubpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.
FDA inspections continue to focus on CGMP violations related to basic GMP controls. A survey of Warning Letters issued in 2013 on CMC (Chemistry / Manufacturing / Controls) violations reveals an emphasis
More informationPharmaceutical Reference Standards: Overview and Role in Global Harmonization
Matthew Borer, Ph.D., Advisor Pharmaceutical Reference Standards: Overview and Role in Global Harmonization 3rd DIA China Annual Meeting Beijing, China, 16-18 May, 2011 What is a Pharmaceutical Reference
More informationThe Impacts of FDA Combination Product Rulings on Medical Devices
The Impacts of FDA Combination Product Rulings on Medical Devices Khaudeja Bano Arlington, VA - June 14 th 2017 15 th Product Complaint Congress for Life Sciences Disclaimer Speaker s personal opinion
More informationEU and FDA GMP Regulations: Overview and Comparison
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational
More informationPlamena Entcheva-Dimitrov, PhD, RAC On-line Course.
Plamena Entcheva-Dimitrov, PhD, RAC On-line Course 1 The Preferred Regulatory Consulting content in this presentation is copyright protected under United States law and applicable international copyright
More informationSan Jose, California, USA
Glisland, Inc. San Jose, California, USA http://www.glisland.com Welcome to the Drug GMP World Current Good Manufacturing Practice cgmp ICH Q10 Pharmaceutical Quality System PQS GMP QSR Quality System
More informationAddressing Key FDA Citations with Training. Align UL EduNeering Courses to Top FDA Warning Letter Topics
Addressing Key FDA Citations with Training Align UL EduNeering Courses to Top FDA Warning Letter Topics Addressing Key FDA Citations with Training Align UL EduNeering Courses to Top FDA Warning Letter
More informationPostmarketing Safety Reporting and cgmp Requirements for Combination Products. Katlin McKelvie Backfield November 2, 2017
Postmarketing Safety Reporting and cgmp Requirements for Combination Products Katlin McKelvie Backfield www.backfieldpllc.com November 2, 2017 Background: What is a Combination Product? Combination product:
More informationLeft to Our Own Devices Design Control & Risk Management Strategies for Combination Products
Left to Our Own Devices Design Control & Risk Management Strategies for Combination Products DR. RICK WEDGE 12 MAR 2018 Overview Definitions Current Regulatory Landscape Design Controls Risk Management
More informationCurrent Good Manufacturing Practice Requirements for Combination Products
[Federal Register: September 23, 2009 (Volume 74, Number 183)] [Proposed Rules] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr23se09-17] -----------------------------------------------------------------------
More informationCBI s 15 th Annual Product Complaints Congress for Life Sciences
CBI s 15 th Annual Product Complaints Congress for Life Sciences June 14, 2017 Steven Niedelman Lead Quality Systems & Compliance Consultant King & Spalding LLP 1700 Pennsylvania Ave., NW Washington, DC
More informationCGMP and Postmarketing Safety Reporting Requirements for Combination Products
CGMP and Postmarketing Safety Reporting Requirements for Combination Products GMP by the Sea August 29, 2017 Mark D. Kramer Regulatory Strategies, Inc. 1 Definition of a Combination Product A combination
More informationHow Pharma Should Monitor itself for GMP Compliance & How FDA Inspections Could Incorporate Pharmaceutical Inspection Cooperation Scheme (PIC/S)
How Pharma Should Monitor itself for GMP Compliance & How FDA Inspections Could Incorporate Pharmaceutical Inspection Cooperation Scheme (PIC/S) ASQ Northeast Pharmaceutical GMP/Quality Conference January
More informationCombination Products: QS & Design Controls Requirements
Combination Products: QS & Design Controls Requirements M. Isabel Tejero, MD PhD Office of Compliance CDRH, FDA Isabel.Tejero@fda.hhs.gov Presentation Goals Introduction to combination product CGMP requirements
More informationUpdate on Regulation of Drug/Device Combination Products Europe and Beyond. Janine Jamieson, Editorial Staff Europe, IPQ Publications
Update on Regulation of Drug/Device Combination Products Europe and Beyond Janine Jamieson, Editorial Staff Europe, IPQ Publications Outline new regulations, guidance, initiatives and conferences.. Background
More informationDocket No. FDA-2015-D-0198: Current Good Manufacturing Practice Requirements for Combination Products.
701 Pennsylvania Avenue, Ste. 800 Washington, DC 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org April 29, 2015 Division of Dockets Management (HFA-305) Food and Drug Administration 5630
More informationThe ABCs and Challenges of GMP The American Experience
The ABCs and Challenges of GMP The American Experience The Canadian Association of Nuclear Medicine Toronto, Ontario April 22, 2017 Reiko Oyama, R.Ph., B.C.N.P. Washington University School of Medicine
More informationAAMI Quality Systems White Paper: Comparison of 21 CFR Part 820 to ISO 13485:2016 1
AAMI s White Paper Comparison of 21 CFR Part 820 to ISO 13485:2016 February 2017 AUTHORS Seb Clerkin, GMP Advisory Services Nicola Martin, Owner, Nicola Martin Consulting Jack Ward, Owner, Ward Sciences
More informationMedical Devices. The technical requirements also apply when the submitter is not the legal manufacturer 1 (i.e: a distribution company).
UNFPA Technical requirements for medical devices 1. Introduction The following document provides UNFPA s technical requirements in the procurement of medical devices (medical equipment, renewable medical
More informationDocket No. FDA-2015-D-0198: Current Good Manufacturing Practice Requirements for Combination Products.
701 Pennsylvania Avenue, Ste. 800 Washington, DC 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org April 29, 2015 Division of Dockets Management (HFA-305) Food and Drug Administration 5630
More informationBridging gaps: medical device directive vs regulation. Geert Corstens 1 November 2018
Bridging gaps: medical device directive vs regulation Geert Corstens 1 November 2018 Agenda Current Medical Device regulatory landscape New Medical Device Regulation EU Interaction & impact Medical device
More informationCopyright GCI, LLC Remediation of Legacy Medical Devices
Copyright GCI, LLC. 2016 Remediation of Legacy Medical Devices Copyright GCI, LLC. 2016 What Drives Legacy Remediation? Proactive Recertification / CE Mark Audit Readiness M&A / Due Diligence Reactive
More informationInterface between medicinal product and medical devices development - Update on EMA implementation of the new medical devices legislation
Interface between medicinal product and medical devices development - Update on EMA implementation of the new medical devices legislation Combined medicines and devices developments SME info day, 26 October
More informationGood Manufacturing Practice ( GMP ) Compliance: GMPs EXPLAINED
Good Manufacturing Practice ( GMP ) Compliance: GMPs EXPLAINED Presented by Raymond A. Bonner Nathan C. Sheers SIDLEY AUSTIN BROWN & WOOD, LLP Washington, D.C. (202) 736-8000 To The Fourth Annual Pharmaceutical
More informationDavid W Feigal, Jr., MD MPH
Global Harmonization Summit Where have we been with Harmonization? David W Feigal, Jr., MD MPH Adjunct Professor, College of Law, Arizona State University Partner, NDA Partners LLP September 18, 2014 Washington
More informationDrug-Device Combination Product Development: INDs for Device Companies
Drug-Device Combination Product Development: INDs for Device Companies David Armbruster Global Program Manager April 24, 2013 Drug-Device Combination Product Development -or- The scenic route to an IND
More informationAugust 14, Dockets Management Staff (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org August 14, 2018 Dockets Management Staff (HFA-305) Food and Drug Administration 5630
More informationThe FDA Just Arrived... Are You Ready? Presented By Sandra Lueken Sr. Director, Quality AstraZeneca Biologics
The FDA Just Arrived... Are You Ready? Presented By Sandra Lueken Sr. Director, Quality AstraZeneca Biologics Objectives Review Quality Systems Audit Approach and cgmp fundamentals Logistical Audit Preparation
More informationThe Medical Device Coordination Group: a new Authority Under EU Device Regulations
The Medical Device Coordination Group: a new Authority Under EU Device Regulations By Robert D. Cumming and Nancy W. Mathewson, Esq. This article discusses the organization and functions of the Medical
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 8 Inspections, Compliance, Enforcement, and Criminal Investigations Lupin Limited 5/7/09 Department of Health and Human Services Public Health Service Food and Drug Administration CENTER FOR
More informationContents. Regulatory Bodies... 13
Contents UNITED STATES... 3 Regulatory Bodies... 3 Product Classification and Regulatory Control... 3 Application Documents... 3 Quality System Requirements... 4 Product and Manufacturer s License... 4
More informationRegulatory Requirements & Recent Changes, including expectations for APIs & IMPs
Regulatory Requirements & Recent Changes, including expectations for APIs & IMPs Neil Raw - GMP Inspector Richard Andrews - Operations Manager 11 th November 2008 Programme: Regulatory Requirements Neil
More informationDECEMBER 2008 GUIDANCE NOTES ON PRODUCT QUALITY REVIEW
DECEMBER 2008 GUIDANCE NOTES ON PRODUCT QUALITY REVIEW 1.0 INTRODUCTION: The purpose of this guidance is to communicate the expectation with regard to the conduct of Product Quality Review. Product Quality
More informationThe Use of Pharmaceutical Stability Tools in Medical Device Stability Programs
Global SYNTHES Institute of Validation Technology Forum on Stability Programs The Use of Pharmaceutical Stability Tools in Medical Device Stability Programs Laure L. Larkin MSc. CPP. Synthes USA 1 The
More informationPerspective: New European IVD Regulations New Concepts for Market Authorizations and Product Launch Schedules
Perspective: New European IVD Regulations New Concepts for Market Authorizations and Product Launch Schedules Planning for Efficiencies of Data, Resources, and Timelines A PRECISION BRIEF Introduction
More informationCOMBINATION PRODUCTS Inspection Readiness and Outcomes
WHITE PAPER COMBINATION PRODUCTS Inspection Readiness and Outcomes Many companies think that because they have a good relationship with the FDA Center they interacted with during their submission reviews
More informationPurchasing Controls. FDA Small Business Regulatory Education for Industry (REdI) Conference Denver, Colorado May 13, 2015
Purchasing Controls FDA Small Business Regulatory Education for Industry (REdI) Conference Denver, Colorado May 13, 2015 LCDR Samantha Spindel, Ph.D. Premarket Programs Branch Division of Industry and
More informationThe Impact of Quality Culture on Quality Risk Management. FDA Perspective on Quality Culture; how it Impacts Risk Management
The Impact of Quality Culture on Quality Risk Management FDA Perspective on Quality Culture; how it Impacts Risk Management Teresa Gorecki Practice Lead Compliance Architects Agenda The WHAT Definitions
More informationCGMP Requirements for Investigational Products
PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health
More informationAAMI Quality Systems White Paper
AAMI s White Paper Comparison of 21 CFR Part 820 to ISO 13485:2016 February 2017, Updated February 2018 AUTHORS Seb Clerkin, GMP Advisory Services Nicola Martin, Owner, Nicola Martin Consulting Jack Ward,
More informationCBER Expectations Regarding Contract Manufacturing
CBER Expectations Regarding Contract Manufacturing LCDR Qiao Bobo, Ph.D. FDA/CBER/OCBQ/DMPQ CASSS CMC Strategy Forum Summer 2014 Outline 2 Types of Cooperative Manufacturing Arrangements CBER Expectations
More informationWebinar Expert Module 3: GMP Inspections Dupont
Webinar Expert Module 3: GMP Inspections Dupont 26 January & 9 February 2018 GOP-Innovations your Partner for Practical Training and e-learning Milenko Pavičić Pharmaceutical microbiologist, trainer, coach
More informationPlanning for and Managing FDA Inspections. Focus: 21 CFR, Part 820
Planning for and Managing FDA Inspections Focus: 21 CFR, Part 820 Information, Preventive Action and Strategy 1 The Authority behind Inspections The Safe Medical Devices Act of 1990 (the SMDA), enacted
More informationGETTING READY FOR THE EUROPEAN UNION (EU) MEDICAL DEVICE REGULATION (MDR)
GETTING READY FOR THE EUROPEAN UNION (EU) MEDICAL DEVICE REGULATION (MDR) Caroline Leab Abbott Director of Regulatory Affairs David Wolf PTC Program Director of Medical Device Strategy liveworx.com NEW
More informationFDA 21 CFR Part 820 vs. ISO 13485:2016 Comparison Table created by greenlight.guru
FDA 21 CFR Part 820 vs. ISO 13485:2016 Comparison Table created by greenlight.guru FDA QSR (21 CFR Part 820) ISO 13485:2016 820.1 Scope 1 Scope 2 Normative References 820.3 Definitions 3 Terms and Definitions
More informationEMA perspective on increasing focus on review of device components of medicinal products
EMA perspective on increasing focus on review of device components of medicinal products TOPRA Annual Human Medicines Symposium 2 4 October 2017 - Victoria Park Plaza Hotel, London Presented by Armin Ritzhaupt,
More informationThe Device Side of Combination Products
The Device Side of Combination Products Technical and Regulatory Challenges in Life Cycle Management Bob Laughner Associate Director, Combination Products 04 May 2016 What are combination products? Combination
More informationCombination Products: A 40 Year Regulatory Evolution
The right people. The right solution. The first time. Combination Products: A 40 Year Regulatory Evolution Technological advances in healthcare products and the delivery of those products will continue
More informationGMP for Medical Devices
GMP for Medical Devices NEW: Update regarding EU Medical Device Regulation and ISO 13485 Revision SPEAKERS: Dr Gerhard Bauer Chemgineering Business Design GmbH Harald Rentschler mdc, medical devices certification
More informationTeleconference Course Materials You may duplicate this for each person attending the conference.
TC140515 Teleconference Course Materials You may duplicate this for each person attending the conference. FDA s Former Director of the Office of Combination Products Looks at the Effects of the New GMP
More informationDesign Quality. Indu Lakshman
Design Quality Indu Lakshman Overview New product development (NPD) covers the complete process of bringing a new product to market. In commercial terms, new product development is described in the literature
More informationFocused Trends from the FDA
Focused Trends from the FDA GXP INSPECTION READINESS Jolly Bhatia Sr. Director, QA Alnylam September 21, 2017 Credits: Tim Maines, Arya Tavana, John French, Roan Martin 13% of FDA Complete Response Letters
More informationPrevent Quality System Deficiencies by Conducting Effective Internal Audits. Whitepaper
Prevent Quality System Deficiencies by Conducting Effective Internal Audits Whitepaper An internal audit system is one of the most effective ways to monitor, analyze, control, and improve quality management
More informationASQ Tappan Zee Section Medical Devices, New Regulations and Standards. 26 th September / V. Fischer / Rev. 01
ASQ Tappan Zee Section Medical Devices, New Regulations and Standards 26 th September / V. Fischer / Rev. 01 Agenda Medical Device, General Aspects Examples Quality System(s) New Regulations & Standards
More informationJournal of Chemical and Pharmaceutical Research
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2011, 3(6):88-98 Conduct of Inspections for Pharmaceutical Manufactures
More informationIVT Laboratory Week Jerry Lanese. Ph.D. The Lanese Group, Inc The Lanese Group, Inc.
IVT Laboratory Week-2015 Jerry Lanese Ph.D. The Lanese Group, Inc. 1 Name Job What brought you here. 2 FDA interest in Quality Metrics What are Quality Metrics Quality metrics FDA will request The impact
More informationRe: Comments on Unique Device Identification System; Proposed Rule; Docket No. FDA-2011-N-0090 / RIN No AG31
1227 25th Street, NW Washington, D.C. 20037-1156 October 24, 2012 VIA ELECTRONIC SUBMISSION Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville,
More informationQuality Risk Management: Excipients
Quality Risk Management: Excipients ExcipientFest 2012 Presented by: Londa Ritchey, M.S. Director, Supplier Qualification Global Quality Operations Pfizer, Inc. Agenda Regulatory Environment Material Quality
More informationPharmaceutical cgmps for the 21st Century February 2004
Pharmaceutical cgmps for the 21st Century February 2004 Ludwig Huber Compliance Fellow for Life Sciences and Chemical Analysis Chairperson: Rob Sample FDA GxP Regulations Along the Drug Life Basic Research
More informationAbbreviated WHO prequalification assessment procedure
Abbreviated WHO prequalification assessment procedure Industry Briefing on Streamlined WHO Prequalification of Diagnostics Procedure 15/16 May 2014, Geneva Anita Sands Prequalification Team Diagnostics
More informationJeff Yuen and Associates, Inc. PO Box 6026 Orange, CA Zenaida Power Regulatory Expertise:
Regulatory Expertise: Pharmaceuticals: Sterile-Liquids, Non-Sterile Liquids, Solid Oral Dosage Form, Parenterals, Antibiotics, APIs/Bulk Chemicals, Creams & Ointments Medical Devices: Implantable / Active
More informationSupply Chain Supplier Quality Management. Nicholas Violand, Investigator/Drug Specialist US FDA, New Jersey District
Supply Chain Supplier Quality Management Nicholas Violand, Investigator/Drug Specialist US FDA, New Jersey District 1 Overview Product Life Cycle Maintaining Quality in Supply Chain FDA and ICH Guidances
More informationAnnual product quality review: Guidance for industry by regulatory perspective
International Journal of Medicine Research ISSN: 2455-7404; Impact Factor: RJIF 5.42 www.medicinesjournal.com Volume 2; Issue 4; July 2017; Page No. 01-10 Annual product quality review: Guidance for industry
More informationABRIDGED PREQUALIFICATION ASSESSMENT. Prequalification of In Vitro Diagnostics
P r e q u a l i f i c a t i o n T e a m - D i a g n o s t i c s ABRIDGED PREQUALIFICATION ASSESSMENT Prequalification of In Vitro Diagnostics PQDx_173 v3 12 September 2017 (This document version supersedes
More informationEU MDR 10 Things Packaging Engineers Should Know
EU MDR 10 Things Packaging Engineers Should Know networkpartners.com NUMBER ONE THE TIME FOR ACTION IS NOW First, some background: The EU Medical Device Regulation (MDR) was approved by the European Parliament
More informationJournal home page: RESEARCH ARTICLE
Journal home page: http://www.journalijiar.com INTERNATIONAL JOURNAL OF INNOVATIVE AND APPLIED RESEARCH RESEARCH ARTICLE QUALITY AUDIT AND GMP INSPECTION OF PHARMACEUTICAL INDUSTRY WITH REFERENCE TO USFDA;
More informationISO and UAV Audits Preparation and Client Rights
1 ISO 13485 and UAV Audits Preparation and Client Rights Medical Devices Quality Management Systems Requirements for Regulatory Purposes 24301 Woodsage Dr. Bonita Springs, FL 34134 (239)-307-6060 www.promedic.cc
More informationRegistration and renewal of the credential certificate for registration
Registration and renewal of the credential certificate for registration 1. Qualification of the applicant: 1.1 Must be a holder of the license to manufacture or import the psychotropic substances of category
More informationCOMBINATION PRODUCTS A RECENT FDA PERSPECTIVE. Sugato De
COMBINATION PRODUCTS A RECENT FDA PERSPECTIVE Sugato De Principal Consultant Integrated Product Development PAREXEL Consulting June 29, 2018 GLOBAL BIO CONFERENCE 2018 2018 PAREXEL INTERNATIONAL CORP.
More informationCMC Strategy Forum Europe 2016
Science-based Development & Licensing of Combination Products Focus on High Concentration Monoclonal Antibody Solutions in Prefilled Syringes or Prefilled Pens Serge Mathonet, Sanofi Global Regulatory
More informationQuality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals
Quality Agreements with CMO s Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals FDA Guidance Contract Manufacturing Arrangements for Drugs: Quality
More informationAn Industry Perspective
Controls An Industry Perspective Presented by: Jay Gerondale Amgen Inc. Overview Why are We Here? What are Controls? Control Elements Product Development Steps Conclusion Bridging Making a Combination
More informationRequirements for Industry PIF. Regional Training on Product Information File (PIF) Product Information File (PIF)
Regional Training on Product Information File (PIF) 10-11 11 June 2007 Vientiane LAO PDR Product Information File (PIF) Requirements for Industry PIF The Company or Person placing a cosmetic product in
More informationGuidance for Industry Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations
Guidance for Industry Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations DRAFT GUIDANCE This draft guidance document is being distributed for comment purposes only.
More informationFDA s Role in Vaccine Supply
IOM Committee on Review of Priorities of the National Vaccine Plan Stakeholder Workshop #1 24 July 2008 FDA s Role in Vaccine Supply Norman W. Baylor, Ph.D., Director Office of Vaccines Research and Review
More informationImpacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales. Innovacion en Packaging Primario
Impacto de las Nuevas Tendencias Regulatorias en la Producción de Parenterales Innovacion en Packaging Primario 1 Contents Company Highlight What s Changing in Pharma Pharma Trends Harmonisation New Requirements
More informationFDA Quality Metrics, Data Integrity and Application of Statistics Throughout Process Validation in a Global Economy
CBI Statistics in Validation FDA Quality Metrics, Data Integrity and Application of Statistics Throughout Process Validation in a Global Economy Jerry Lanese Ph.D. The Lanese Group, Inc. 2017 The Lanese
More informationEU Annex 11 US FDA 211, 820, 11; other guidelines Orlando López 11-MAY-2011
Principle. a. This annex applies to all forms of computerised systems used as part of a GMP regulated activities. A computerised system is a set of software and hardware components which together fulfill
More informationDRUG DRAFT GUIDELINE FOR REGISTRATION OF MEDICAL DEVICES FOR HUMAN USE IN UGANDA, SEPTEMBER 2009
DRUG NATIONAL AUTHORITY DRAFT GUIDELINE FOR REGISTRATION OF MEDICAL DEVICES FOR HUMAN USE IN UGANDA, SEPTEMBER 2009 TABLE OF CONTENTS: 1 INTRODUCTION 2 DEFINITION OF MEDICAL DEVICE 3 SCOPE OF THE GUIDELINE
More informationMedical Device Purchasing Controls Challenges of Compliance in a World Market June, 2013 OMTEC
Medical Device Purchasing Controls Challenges of Compliance in a World Market June, 2013 OMTEC - 2013 Quality Business Acceptance Activities 1 ..FDA Across the Globe.. 2 ..Warning Letters and FDA 483 update..
More informationGxP Auditing, Remediation, and Quality System Resourcing
GxP Auditing, Remediation, and Quality System Resourcing TABLE OF CONTENTS 3 Introduction 4 GxP Auditing 4 GMP Auditing 5 GCP Auditing 6 GLP Auditing 7 Pharmacovigilance Auditing 7 Vendor/Supplier Auditing
More informationQuality Agreements and Managing Contract Supplier Quality
Quality Agreements and Managing Contract Supplier Quality American Society for Quality Lloyd Bailey November 3, 2005 Service Mark of The Dow Chemical Company TM Trademark of The Dow Chemical Company Abstract
More informationDisclosures. Laboratory Stakeholders. IVD vs. LDT. FDA Regulation of Laboratory Developed Tests 10/2/2015. FDA Regulation of LDTs
Disclosures FDA Regulation of Laboratory Developed Tests Beaumont Health System, 24 th Annual Symposium on Molecular Pathology September 16, 2015 Roger D. Klein, MD JD Director, Molecular Pathology Clinical
More informationStability and Shelf Life of Combination Products. John McMichael FDA/CDRH
Stability and Shelf Life of Combination Products John McMichael FDA/CDRH Combination Products Regulations under 21 CFR 4.4(b) provides that combination product manufacturers may meet the requirements of
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Inspections, Compliance, Enforcement, Criminal Investigations Crothall Healthcare, Inc. Department of Health Human Services Public Health Service Food Drug Administration New Orleans District 404 BNA Drive
More informationGMP The Other Side of Chemistry, Manufacturing & Controls (CMC)
Overview of USFDA Drug Regulatory Requirements Pharmaceutical Quality and Facility Inspections (GMP) Session II 19 February 2014 Casablanca, Morocco GMP The Other Side of Chemistry, Manufacturing & Controls
More informationEMPROVE For Raw and Starting Materials & For Filtration Devices and Single Use Systems. Jan Thomsen Warsaw, November 15 th, 2016
EMPROVE For Raw and Starting Materials & For Filtration Devices and Single Use Systems Jan Thomsen Warsaw, November 15 th, 2016 2 Content Emprove - An Introduction Emprove for Raw and Starting Materials
More informationComparative Overview of Other Medical Devices Regulatory Systems
Comparative Overview of Other Medical Devices Regulatory Systems Dr David Jefferys, BSc MD, FRCP, FFPM Medical Device Expert Senior Vice President Global Regulatory, Healthcare Policy and Corporate Affairs
More information